(Q46224909)

20 December 2017

review article

1 reference

title

Pathogenesis of myeloma bone disease (English)

1 reference

20 December 2017

author name string

G D Roodman

series ordinal

1

1 reference

20 December 2017

publication date

27 November 2008

1 reference

20 December 2017

published in

Leukemia

1 reference

20 December 2017

volume

23

1 reference

20 December 2017

page(s)

435-441

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.336

exact match

0 references

cites work

Pathogenesis of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

The pathogenesis of the bone disease of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Perspective on the osteoclast: an angiogenic cell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Treatment strategies for bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Minireview: transcriptional regulation in development of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Wnt signaling in osteoblasts and bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

21 January 2018

Bone disease in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Proteasome inhibition in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

New Insights in Myeloma-induced Osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Thalidomide and lenalidomide in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Fracture risk with multiple myeloma: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.336

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.336

1 reference

20 December 2017

Dimensions Publication ID

0 references

1 reference

20 December 2017